Healthcare
Humacyte, Inc.(HUMAW)
Live Price
Offline$0.11
+0.00% today
1Y Change
-97.93%
Window
Jun 27, 2025 โ Jun 23, 2026
- Market Cap
- $130.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +79.4%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 27, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Humacyte, Inc. (HUMAW) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $0.11 and down 97.9% across the available one-year price window (Jun 27, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +79.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +79.4%, free cash flow -6.3% with operating margin -5306.0% and ROIC -107.7%. Valuation already assumes a fairly strong business story at price/sales 64.8. Stock Foundry combines HUMAW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-5306.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +79.4%, while operating margin sits near -5306.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 27, 2026 | +1.3% | +0.0% | +0.0% | +0.0% |
2025 Nov 12, 2025 | +26.8% | +7.6% | -26.3% | -35.2% |
Benchmark Edge
HUMAW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HUMAW
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HUMAW Max Drawdown
-98.56%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HUMAW and SPY.
Company Overview
Humacyte, Inc.
NASDAQ Global Select
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
- Leadership
- Laura E. Niklason
- IPO Date
- Dec 1, 2020
- Employees
- 218
- Street Address
- 2525 East North Carolina Highway 54
- Mailing
- Durham, DE, 27713
- Region
- Durham, DE, US
- Reporting Currency
- USD
- Investor Line
- 919 313 9633
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 64.8
- Price/Book
- 42.8
Growth
- Revenue
- 0.0%
- EPS
- +79.4%
- Free Cash Flow
- -6.3%
Profitability
- Gross Margin
- -736.5%
- Operating Margin
- -5306.0%
- Net Margin
- -2003.6%
- ROE
- -424.8%
- ROIC
- -107.7%
Balance Sheet
- Debt/Equity
- 20.86
- Current Ratio
- 3.69
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.